A Review of Current Management of Gestational Trophoblastic Disease



Abstract Views
1134

Downloads
607

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Jul 3, 2022
Published Sep 29, 2022
10.24018/ejmed.2022.4.5.1403

Abstract viewed = 1134 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

A set of conditions connected to pregnancy and caused by trophoblast cells are known as gestational trophoblastic diseases. There are benign and malignant cancers, including invasive moles, choriocarcinomas, placental site trophoblastic tumors (PSTT), and epithelioid trophoblastic tumors (ETT). These cancers are classified as gestational trophoblastic neoplasms (GTN), which are less common but more serious. Most often, monitoring serum human chorionic gonadotropin (hCG) with histological confirmation is used to diagnose GTN. As a differential diagnosis, certain tissue biomarkers have grown in popularity. This has produced more accurate results and various treatment regimens and prognoses for each GTN. The World Health Organization's prognostic score system and the International Federation of Gynecology and Obstetrics anatomical staging system are the foundations for the treatment. Suppose the proper diagnosis is made and the instructions are followed. In that case, choriocarcinoma and invasive mole cases can be cured in 98 percent of instances, whereas PSTT and ETT still have only moderate success rates. The increased understanding of GTN and its characteristics enables medical professionals to rapidly make a differential diagnosis and select the appropriate treatment option, thus improving the overall survival of affected women. Nevertheless, epidemiological data collection and knowledge advancement through basic and translational research are crucial to address issues regarding GTN pathophysiology, their origins, and cellular behaviour.

Keywords: Gestational trophoblastic diseases, human chorionic gonadotropin, treatment

Downloads

Download data is not yet available.

References

  1. Osborne R, Dodge J. Gestational trophoblastic neoplasia. Obstet Gynecol Clin North Am. 2012; 39(2): 195-212.
    DOI  |   Google Scholar
  2. Freitas F, Braga A, Viggiano M, Velarde LGC, Maesta I, Uberti E, et al. Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study. Gynecol Oncol. 2020; 158(2): 452-459.
    DOI  |   Google Scholar
  3. Goldstein DP, Berkowitz RS. Current management of gestational trophoblastic neoplasia. Hematol Oncol Clin North Am. 2012; 26(1): 111-131.
    DOI  |   Google Scholar
  4. Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet. 2018; 143 Suppl 2: 79-85.
    DOI  |   Google Scholar
  5. Chauhan M, Behera C, Madireddi S, Mandal S, Khanna SK. Sudden death due to an invasive mole in a young primigravida: Precipitous presentation masquerading the natural manner. Med Sci Law. 2018; 58(3): 189-193.
    DOI  |   Google Scholar
  6. Gadducci A, Carinelli S, Guerrieri ME, Aletti GD. Placental site trophoblastic tumor and epithelioid trophoblastic tumor: Clinical and pathological features, prognostic variables and treatment strategy. Gynecol Oncol. 2019; 153(3): 684-693.
    DOI  |   Google Scholar
  7. Eysbouts YK, Bulten J, Ottevanger PB, Thomas CMG, Ten Kate-Booji MJ, Van Herwaarden AE, et al. Trends in incidence for gestational trophoblastic disease over the last 20 years in a population-based study. Gynecol Oncol. 2016; 140(1): 70-75.
    DOI  |   Google Scholar
  8. Stockton L, Green E, Kaur B, De Winton E. Non-Gestational Choriocarcinoma with Widespread Metastases Presenting with Type 1 Respiratory Failure in a 39-Year-Old Female: Case Report and Review of the Literature. Case Rep Oncol. 2018; 11(1): 151-158.
    DOI  |   Google Scholar
  9. Guo N, Yin R, Li Q, Song L, Wang D. Postmenopausal choriocarcinoma: a rare case report and review of the literature. Menopause. 2018; 25(2): 239-241.
    DOI  |   Google Scholar
  10. Hui P. Gestational Trophoblastic Tumors: A Timely Review of Diagnostic Pathology. Arch Pathol Lab Med. 2019; 143(1): 65-74.
    DOI  |   Google Scholar
  11. Mao TL, Shih IeM. Advances in the diagnosis of gestational trophoblastic tumors and tumor-like lesions. Expert Opin Med Diagn. 2009; 3(4): 371-380.
    DOI  |   Google Scholar
  12. Savage J, Adams E, Veras E, Murphy KM, Ronnett BM. Choriocarcinoma in Women: Analysis of a Case Series With Genotyping. Am J Surg Pathol. 2017; 41(12): 1593-1606.
    DOI  |   Google Scholar
  13. Seckl MJ, Sebire NJ, Fisher RA, Golfier F, Massuger L, Sessa C. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2013; 24 Suppl 6:vi39-vi50.
    DOI  |   Google Scholar
  14. Pires KSN, Sun SY, Gonçalves CM, Santos JC, Tenorio LP, Botelho RM, et al. Versican silencing in BeWo cells and its implication in gestational trophoblastic diseases. Histochem Cell Biol. 2019; 151(4): 305-313.
    DOI  |   Google Scholar
  15. Shu H, Chen H, Yang B, Chang Z, Xiong M, Chen W. Aberrant expression of E-cadherin and integrin β-1 in trophoblasts is associated with malignant gestational trophoblastic diseases. Int J Gynecol Cancer. 2013; 23(4): 749-754.
    DOI  |   Google Scholar
  16. Li J, Yue H, Wang X, Chen R, Lu X. Chemotherapy for gestational trophoblastic neoplasia patients with a FIGO score of 12 or greater: A multistudy analysis. Eur J Obstet Gynecol Reprod Biol. 2019; 238: 164-169.
    DOI  |   Google Scholar
  17. Rezende Filho J, Montenegro CA, Rezende Obstetrícia, 13 ed., Guanabara Koogan, Rio de Janeiro, 2014.
     Google Scholar
  18. Froeling FE, Seckl MJ. Gestational trophoblastic tumours: an update for 2014. Curr Oncol Rep. 2014; 16(11): 408.
    DOI  |   Google Scholar
  19. Ghorani E, Kaur B, Fisher RA, Short D, Joneborg U, Carlson JW, et al. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. Lancet. 2017; 390(10110): 2343-2345.
    DOI  |   Google Scholar
  20. You B, Bolze PA, Lotz JP, Massardier J, Gladieff L, Joly F, et al. Avelumab in patients with gestational trophoblastic tumors with resistance to single-agent chemotherapy: cohort A of the TROPHIMMUN phase II trial. J Clin Oncol. 2020; 38 (27): 3129–3137.
    DOI  |   Google Scholar
  21. Yang J, Zong L, Wang J, Wan X, Feng F, Xiang Y. Epithelioid Trophoblastic Tumors: Treatments, Outcomes, and Potential Therapeutic Targets. J Cancer. 2019; 10(1): 11-19.
    DOI  |   Google Scholar


Most read articles by the same author(s)

1 2 3 > >>